Revenues double at pharma firm as it hails ‘ground-breaking’ clinical results
Avacta Life Sciences saw its half yearly revenues double to £11.9m in the six months to the end of June. Its EBITDA losses increased from £5.4m in the first half of last year to £7.9m this year.
The Wetherby firm's AVA6000 continues to perform well in clinical trials - chairman Dr Eliot Forster described the results as "ground-breaking" - and the acquisition of Belgium-based Coris Bioconcept for its diagnostics division will help move that arm closer to profit, the firm said. The therapeutics arm recorded an EBITDA loss of £0.4... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
